EBS vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

EBS

34.6
AI Score
VS
PCRX Wins

PCRX

55.8
AI Score

Investment Advisor Scores

EBS

35score
Recommendation
AVOID NEW MONEY

PCRX

56score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric EBS PCRX Winner
Forward P/E 22.9885 6.25 PCRX
PEG Ratio 0.3835 11.2121 EBS
Revenue Growth 66.3% 6.2% EBS
Earnings Growth -93.8% -30.0% PCRX
Tradestie Score 34.6/100 55.8/100 PCRX
Profit Margin -23.0% 2.0% PCRX
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD PCRX

Relative Price Performance (Last 90 Days)

EBS 1M: -2.0% · 3M: -22.6% PCRX 1M: -5.2% · 3M: -1.5%

Current Technical Phase

EBS

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -8.9%) with fading momentum, RSI 48

RSI (14): 47.8 · Price: $6.33

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 50.7 · Price: $25.21

Fundamentals Snapshot

Metric EBS PCRX
Market Cap — —
Forward P/E 6.1 7.3
Trailing P/E — 71.5
Revenue (TTM) — —
Revenue Growth 0.7% 0.1%
Gross Margin 0.5% 0.8%
Operating Margin 0.3% 0.1%
EPS -3.29 0.35
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.